Solutions for gluten-related disorders
Targeted enzymatic digestion of gluten immunogenic peptides
A unique approach
Scientific research has shown that partially digested gluten fragments, known as gluten immunogenic peptides (GIPs) trigger an autoimmune response in genetically predisposed people, namely celiac disease.
GIPs also play a role in the immune pathology of non-celiac gluten sensitivity, a clinical syndrome distinct from celiac disease.
AMYRA has developed a unique technology able to target GIPs in the intestine, where the pathology of celiac disease and non-celiac gluten sensitivity takes place.
AMYRA’s novel exopeptidase combinations have demonstrated
rapid and complete digestion of GIPs down to physiologically harmless amino-acids.